Bajorek Beata, Saxton Brooke, Anderson Elizabeth, Chow Clara K
1 Graduate School of Health, University of Technology Sydney, Broadway, NSW, Australia.
4 Department of Pharmacy, Royal North Shore Hospital, Sydney, NSW, Australia.
Eur J Cardiovasc Nurs. 2018 Jun;17(5):429-438. doi: 10.1177/1474515117739618. Epub 2017 Nov 1.
For both patients and clinicians, differences between older and new anticoagulants have major implications for treatment selection, day-to-day management of therapy and adherence.
To explore patients' preferences for warfarin versus direct oral anticoagulant (DOAC) therapy.
Mixed-method study involving anticoagulated older patients admitted to hospital. Part A comprised a vignette-based questionnaire; patients were asked whether they preferred Medicine A (warfarin) or Medicine B (DOAC). Part B interviews explored patients' satisfaction with their current anticoagulant. Responses were thematically analysed.
Forty patients participated: 23 warfarin-treated, 17 DOAC-treated. Collectively, Parts A and B identified that most patients were satisfied with their current therapy (warfarin or DOAC), expressing reluctance to change to alternatives. Among patients who were able to numerically rate their satisfaction with therapy, most were 'satisfied' with their current anticoagulant, although warfarin-treated patients were slightly less 'satisfied' (median score 3.5) than those on DOACs (median score 5.0). Despite this, warfarin-treated patients still preferred their current therapy (over DOACs) due to familiarity and the security of regular international normalised ratio (INR) monitoring; those who preferred DOACs cited previous warfarin-related bleeding and unstable INRs as key reasons. DOAC-treated patients who preferred warfarin perceived regular monitoring as a major advantage; only those having had negative experiences with warfarin clearly preferred DOACs.
Most patients accepted their currently prescribed anticoagulant, be it warfarin or DOACs. Features of specific anticoagulants, such as regular monitoring with warfarin, were perceived variably - some patients cited them as advantages and others as disadvantages. The clearest preference identified was for the agent already being taken.
对于患者和临床医生而言,新型抗凝剂与传统抗凝剂之间的差异对治疗选择、日常治疗管理及依从性均具有重大影响。
探讨患者对华法林与直接口服抗凝剂(DOAC)治疗的偏好。
采用混合方法研究,纳入住院的接受抗凝治疗的老年患者。A部分为基于 vignette 的问卷调查,询问患者更倾向于药物A(华法林)还是药物B(DOAC)。B部分访谈则探讨患者对当前抗凝剂的满意度。对回答进行主题分析。
40名患者参与研究,其中23名接受华法林治疗,17名接受DOAC治疗。综合A、B两部分结果发现,大多数患者对当前治疗(华法林或DOAC)感到满意,不愿更换为其他药物。在能够对治疗满意度进行数字评分的患者中,大多数对当前抗凝剂“满意”,尽管接受华法林治疗的患者满意度略低于接受DOAC治疗的患者(中位数评分分别为3.5和5.0)。尽管如此,接受华法林治疗的患者由于熟悉该药物以及定期国际标准化比值(INR)监测带来的安全感,仍更倾向于当前治疗(相较于DOAC);而倾向于DOAC的患者则将既往华法林相关出血及INR不稳定作为主要原因。接受DOAC治疗且倾向于华法林的患者认为定期监测是一个主要优势;只有那些有过华法林负面经历的患者才明确更倾向于DOAC。
大多数患者接受当前开具的抗凝剂,无论是华法林还是DOAC。特定抗凝剂的特征,如华法林的定期监测,患者的看法不一,一些患者将其视为优势,另一些则视为劣势。最明显的偏好是患者目前正在服用的药物。